Ordering Recommendation
Use to assess genetic risk of abnormal drug metabolism for CYP2B6 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP2B6.
Mnemonic
Methodology
Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
Performed
Varies
Reported
5-10 days
New York DOH Approval Status
Specimen Required
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Refrigerated.
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month
Reference Interval
By report
Interpretive Data
Refer to report.
Laboratory Developed Test (LDT)
Note
Whole blood is the preferred specimen. Saliva samples that yield inadequate DNA quality and/or quantity will be reported as inconclusive if test performance does not meet laboratory-determined criteria for reporting.
Hotline History
Hotline History
CPT Codes
81479
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
3004492 | 2B6 Specimen | 66746-9 |
3004493 | CYP2B6 Genotype | 72882-4 |
3004494 | CYP2B6 Phenotype | 79720-9 |
3004495 | 2B6 Interpretation | 77202-0 |
Aliases
- 2B6
- bupropion
- CYP2B6
- Cytochrome P450 2B6
- efavirenz
- methadone
- nevirapine